Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.

Leukemia research - 1 Jan 2012

Intermesoli Tamara, Castagnetti Fausto, Soverini Simona, Bussini Adelaide, Spinelli Orietta, Gnani Alessandra, Bassan Renato, Rosti Gianantonio

Abstract excerpt

No abstract is available from the source.

Topics

Join the communities discussing this publication.

Benzamides
Biomarkers, Pharmacological
Dasatinib
Fusion Proteins, bcr-abl
Imatinib Mesylate
Phenylalanine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Remission Induction

Source

Identifiers

PMID: 21962337
DOI: 10.1016/j.leukres.2011.09.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.PMID 21962337Read ↗

Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation.Semantic proximity Read ↗

Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.Semantic proximity Read ↗

Third-generation tyrosine kinase inhibitors and beyond.Semantic proximity Read ↗

Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.Semantic proximity Read ↗

Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.Semantic proximity Read ↗

Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.Semantic proximity Read ↗

Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.Semantic proximity Read ↗

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.Semantic proximity Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.Semantic proximity Read ↗

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.Semantic proximity Read ↗

Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.